TGFB1 and Hepatic fibrosis: The result showed that this system was a promising drug delivery system because it could effectively deliver ASO to the liver, downregulate the expression of TGF-β1 mRNA and protein in the liver for the alleviation of liver fibrosis damage, and showed a similar target-gene silencing effect in vitro and in vivo compared with clinically approved liver-targeting ligand GalNAc3 (Figure 10D).